Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Primary treatment and prognostic factors of small cell neuroendocrine carcinoma of the uterine cervix: A Taiwanese Gynecologic Oncology Group study.
Wang KL, Chang TC, Jung SM, Chen CH, Cheng YM, Wu HH, Liou WS, Hsu ST, Ou YC, Yeh LS, Lai HC, Huang CY, Chen TC, Chang CJ, Lai CH.
Eur J Cancer. 2012 Jan 13. [Epub ahead of print]
Related citations
Subjective assessment by ultrasound is superior to the risk of malignancy index (RMI) or the risk of ovarian malignancy algorithm (ROMA) in discriminating benign from malignant adnexal masses.
Van Gorp T, Veldman J, Van Calster B, Cadron I, Leunen K, Amant F, Timmerman D, Vergote I.
Eur J Cancer. 2012 Jan 5. [Epub ahead of print]
Five-year quality of life of endometrial cancer patients treated in the randomised Post Operative Radiation Therapy in Endometrial Cancer (PORTEC-2) trial and comparison with norm data.
Nout RA, Putter H, Jürgenliemk-Schulz IM, Jobsen JJ, Lutgens LC, van der Steen-Banasik EM, Mens JW, Slot A, Stenfert Kroese MC, Nijman HW, van de Poll-Franse LV, Creutzberg CL.
Eur J Cancer. 2011 Dec 14. [Epub ahead of print]
SNP285C modulates oestrogen receptor/Sp1 binding to the MDM2 promoter and reduces the risk of endometrial but not prostatic cancer.
Knappskog S, Trovik J, Marcickiewicz J, Tingulstad S, Staff AC; MoMaTEC study group, Romundstad P, Hveem K, Vatten L, Salvesen HB, Lønning PE.
Eur J Cancer. 2011 Nov 24. [Epub ahead of print]
Body mass index does not influence post-treatment survival in early stage endometrial cancer: results from the MRC ASTEC trial.
Crosbie EJ, Roberts C, Qian W, Swart AM, Kitchener HC, Renehan AG.
Eur J Cancer. 2012 Apr;48(6):853-64. Epub 2011 Nov 17.
Concurrent infections with multiple human papillomavirus (HPV) types in the New Technologies for Cervical Cancer (NTCC) screening study.
Carozzi F, Ronco G, Gillio-Tos A, Marco LD, Mistro AD, Girlando S, Franceschi S, Plummer M, Vaccarella S; For the New Technologies for Cervical Cancer screening (NTCC) Working Group.
Eur J Cancer. 2011 Nov 14. [Epub ahead of print]
Prognostic evaluation of tumour type and other histopathological characteristics in advanced epithelial ovarian cancer, treated with surgery and paclitaxel/carboplatin chemotherapy: Cell type is the most useful prognostic factor.
Bamias A, Sotiropoulou M, Zagouri F, Trachana P, Sakellariou K, Kostouros E, Kakoyianni K, Rodolakis A, Vlahos G, Haidopoulos D, Thomakos N, Antsaklis A, Dimopoulos MA.
Eur J Cancer. 2011 Oct 31. [Epub ahead of print]
p53 Regulates insulin-like growth factor-I receptor gene expression in uterine serous carcinoma and predicts responsiveness to an insulin-like growth factor-I receptor-directed targeted therapy.
Attias-Geva Z, Bentov I, Kidron D, Amichay K, Sarfstein R, Fishman A, Bruchim I, Werner H.
Eur J Cancer. 2011 Oct 25. [Epub ahead of print]
Clinical management of primary vulvar cancer.
Woelber L, Kock L, Gieseking F, Petersen C, Trillsch F, Choschzick M, Jaenicke F, Mahner S.
Eur J Cancer. 2011 Oct;47(15):2315-21. Epub 2011 Jul 4. Review.
Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer.
Vergote I, Amant F, Kristensen G, Ehlen T, Reed NS, Casado A.
Eur J Cancer. 2011 Sep;47 Suppl 3:S88-92. Review.
Cancer and pregnancy: what should we know about the management with systemic treatment of pregnant women with cancer?
Pavlidis N.
Eur J Cancer. 2011 Sep;47 Suppl 3:S348-52. Review.
Uterine sarcomas: a multidisciplinary challenge.
Casali PG, Sanfilippo R.
Eur J Cancer. 2011 Sep;47 Suppl 3:S326-7. Review. No abstract available.
The role of targeted therapy in ovarian cancer.
Banerjee S, Kaye S.
Eur J Cancer. 2011 Sep;47 Suppl 3:S116-30. Review.
Clinical trials and decision-making strategies for optimal treatment of relapsed ovarian cancer.
Ledermann JA, Raja FA.
Eur J Cancer. 2011 Sep;47 Suppl 3:S104-15. Review.
Chairperson's introduction: Surgical skills, especially in the upper abdomen, remain pivotal in the treatment of advanced ovarian cancer.
Vergote I.
Eur J Cancer. 2011 Sep;47 Suppl 3:S86-7. No abstract available.
Adverse reproductive effects of treatment for cancer in childhood and adolescence.
Winther JF, Olsen JH.
Eur J Cancer. 2011 Sep;47 Suppl 3:S230-8. Review. No abstract available.
What makes a good pathology report?
Nobile A, Treboux A, Delaloye JF, Zaman K, Jeanneret-Sozzi W, Schaefer SC, Lehr HA.
Eur J Cancer. 2011 Sep;47(14):2082-3. Epub 2011 Jul 19. No abstract available.
CA125 (MUC16) gene silencing suppresses growth properties of ovarian and breast cancer cells.
Reinartz S, Failer S, Schuell T, Wagner U.
Eur J Cancer. 2011 Aug 16. [Epub ahead of print]
Primary versus secondary cytoreduction for epithelial ovarian cancer: a paired analysis of tumour pattern and surgical outcome.
Braicu EI, Sehouli J, Richter R, Pietzner K, Lichtenegger W, Fotopoulou C.
Eur J Cancer. 2012 Mar;48(5):687-94. Epub 2011 Jul 13.
Omission of excisional therapy is associated with an increased risk of invasive cervical cancer after cervical intraepithelial neoplasia III.
Rapiti E, Usel M, Neyroud-Caspar I, Merglen A, Verkooijen HM, Vlastos AT, Pache JC, Kumar N, Bouchardy C.
Eur J Cancer. 2012 Apr;48(6):845-52.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on